401519-96-8
401519-96-8 性质
| 沸点 | 758.3±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.198±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 酸度系数(pKa) | 14.79±0.70(Predicted) |
| 颜色 | 白色至米白色 |
401519-96-8 用途与合成方法
|
Human Endogenous Metabolite
|
NCX-1000 (15 mg/kg, p.o.) prevents ascite formation, reduces collagen deposition in CCl4-treated rats. NCX-1000 administration almost completely reverts portal hypertension induced by CCl4, and reduces portal pressure in cirrhotic rats. NCX-1000 reverts HSC contraction induced by FCS, and also inhibits MCP-1 release from HSCs stimulated with TNF-α and IFN-γ. NCX-1000 (28 mg/kg, p.o.) decreases portal pressure without affecting mean arterial pressure and heart rate in rats. NCX-1000 also reduces vasoconstriction by 60% caused by 30 μM NE in rats. Administration of NCX-1000 to BDL and sham operated rats results in a similar increase of nitrite/nitrate and cGMP concentrations in the liver.
401519-96-8 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-U00023 | 401519-96-8 | 401519-96-8 | 1 mg | 2906 |
| 2026-09-15 | HY-U00023 | 401519-96-8 | 401519-96-8 | 10 mM * 1 mL in DMSO | 10962 |